Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 1, 2005, Pages 36-43

  Jensen, Harold ^a   Zerouala, Chaouki ^b   Carrier, Michel ^c   Short, Brian ^a  

^a ALLERGAN INC   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; HEPTANOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA; CORNEA ULCER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; INOCULATION; KERATITIS; MAINTENANCE DRUG DOSE; MALE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RABBIT; SCORING SYSTEM;

EID: 14044278165     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.36     Document Type: Article

References (20)

1. Wilhelmus, K.R. Bacterial keratitis. In: Pepose, J.S., Holland, G.N., and Wilhelmus, K.R., eds. Ocular Infection and Immunity. St. Louis, MO: Mosby; 1996:1552.
2. Alexandrakis, G., Alfonso, E.C., and Miller, D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 107:1497-1502, 2000.
3. Drlica, K. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. 2:504-508, 1999.
4. Bauernfeind, A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651, 1997.
5. de Azavedo, J.C., Trpeski, L., Pong-Porter, S., et al. In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group Streptococci from across Canada. Antimicrob. Agents Chemother. 43:2299-2301, 1999.
6. Fung-Tomc, J., Minassian, B., Kolek, B., et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J. Antimicrob. Chemother. 45:437-446, 2000.
7. Fung-Tomc, J., Gradelski, E., Huczko, E., et al. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants. Int. J. Antimicrob. Agents 18:77-80, 2001.
8. Huczko, E., Conetta, B., Bonner, D., et al. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials, 1997-1998. Int. J. Antimicrob. Agents 16:401-405, 2000.
9. Schmitz, F.J., Boos, M., Mayer, S., et al. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:2666-2667, 2001.
10. Fukuda, H., Kishii, R., Takei, M., et al. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:1649-1653, 2001.
11. Ince, D., and Hooper, D.C. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2755-2764, 2001.
12. Takei, M., Fukuda, H., Kishii, R., et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547, 2001.
13. Grasela, D.M. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin. Infect. Dis. 31(Suppl. 2): S51-S58, 2000.
14. Casillas, J.L., Rico, G., Rodriguez-Parga, D., et al. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections. Adv. Ther. 17:263-271, 2000.
15. Ball, P. New antibiotics for community-acquired lower respiratory tract infections: Improved activity at a cost? Int. J. Antimicrob. Agents. 16:263-272, 2000.
16. Gajjar, D.A., LaCreta, F.P., Uderman, H.D., et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 20:49S-58S, 2000.
17. Yamamoto, T., Tsurumaki, Y., Takei, M., et al. In vitro method for prediction of the phototoxic potentials of fluoroquinolones. Toxicol. In Vitro. 15:721-727, 2001.
18. Gritz, D.C., McDonnell, P.J., Lee, T.Y., et al. Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model. Cornea 11:143-147, 1992.
19. Hancock, R.E., and Speert, D.P. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and impact on treatment. Drug Resist. Update 3:247-255, 2000.
20. Eiferman, R.A., Snyder, J.P., and Nordquist, R.E. Ciprofloxacin microprecipitates and macroprecipitates in the human corneal epithelium. J. Cataract Refract. Surg. 27:1701-1702, 2001.